AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions
🔎 AstraZeneca narrows path for failed antibody: The company announced last summer that its monoclonal antibody anselamimab missed the primary endpoint in a pair of Phase 3 trials for patients with ...
May 29, 2026 11:30 AM EDTUpdated 01:15 PM News Briefing AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions ENDPOINTS 🔎 AstraZeneca narrows path for failed antibody: The company announced last summer that its monoclonal antibody anselamimab missed the primary endpoint … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that